Biogen Idec 8-K 2005
Washington, D.C. 20549
Date of Report (Date of earliest event reported): February 17, 2005
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (617) 679-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
TABLE OF CONTENTS
Item 8.01 Other Events
On February 17, 2005, the Registrant publicly disseminated a press release announcing that the Phase 3 TYSABRI® (natalizumab) AFFIRM monotherapy study achieved the two-year primary endpoint of slowing the progression of disability in patients with relapsing forms of multiple sclerosis and that the rate of clinical relapses, the studys primary endpoint at one-year, was sustained over two years and consistent with previously reported one-year results. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 22, 2005